Factors of unfavorable prognosis of endovascular interventions in patients with dysfunctional myocardium and concomitant diabetes mellitus type 2

Abstract


Aim. Study of the features of endovascular intervention, correction of the lipid and carbohydrate metabolism as well as the role of myocardial visualization methods and their effect on delayed results of treatment of patients with left ventricular dysfunctional myocardium and concomitant diabetes mellitus.

Methods. The analysis of the treatment results of patients with dysfunctional myocardium and concomitant diabetes mellitus type 2 was performed. The analysis included 112 patients. The comparison group included 102 patients without diabetes. Visualization of postinfarction myocardial changes was performed with the use of magnetic resinance imaging of the heart both before and after the assessment of the delayed results.

Results. After 18-months follow-up mortality from cardiovascular comlications as well as the rate of major cardiac events was similar to that among patients without diabetes (1.8 and 1%; 6.25 and 3.92%, respectively). The similar tendency was observed 24 months after the intervention (3.3 and 2.3%; 9.8 and 5.7%, respectively). Among the factors associated with the development of such complications are preoperative values of glycosylated hemoglobin ≥6.5%, fasting plasm level of glucose ≥6.0 mmol/l, total cholesterol ≥5.2%, triglycerides ≥1,7 mmol/l, low-density lipoproteins ≥2.5 mmol/l. Also percutaneous coronary intervention later than 30 days after the myocardial infarction and incomplete myocardial revascularization, SYNTAX score >25, transmurality index ≥0.45, cardiac fibrosis ≥45% and presence of diabetes mellitus were prognostically unfavorable risk factors of cardiovascular events.

Conclusion. In patients with left ventricular dysfunctional myocardium and concomitant diabetes mellitus higher efficacy of endivascular intervention was observed and the prevalence of major cardiac events was camparable to the patients without diabetes; delayed percutaneous coronary intervention, incomplete myocardial revascularization, high indices of transmurality and cardiac fibrosis are prognostically unfavorable risk factors of cardiovascular events.


Ya K Rustamova

Azerbaijan Medical University

Author for correspondence.
Email: yasmin.rst@gmail.com

Azerbaijan, Baku, Azerbaijan

G G Imanov

Azerbaijan Medical University

Email: yasmin.rst@gmail.com

Azerbaijan, Baku, Azerbaijan

V. A Azizov

Azerbaijan Medical University

Email: yasmin.rst@gmail.com

Azerbaijan, Baku, Azerbaijan

T S Dzhakhangirov

D.M. Abdullaev Research Institute of Cardiology

Email: yasmin.rst@gmail.com

Azerbaijan, Baku, Azerbaijan

D A Maksimkin

Peoples' Friendship University of Russia

Email: yasmin.rst@gmail.com

Russian Federation, Moscow, Russia

  1. Guariguata L., Whiting D.R., Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 2014; 103: ­137–149. doi: 10.1016/j.diabres.2013.11.002.
  2. Shaw L.J., Cerqueira M.D., Brooks M.M. et al. Impact of left ventricular function and the extent of ische­mia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J. Nucl. Cardiol. 2012; 19 (4): 658–569. doi: 10.1007/s12350-012-9548-3.
  3. Farkouh M.E., Domanski M., Sleeper L.A. et al. Strategies for multivessel revascularization in patients with diabetes. N. Engl. J. Med. 2012; 367: 2375–2384. doi: 10.1056/NEJMoa1211585.
  4. Luthra S., Leiva-Juárez M.M., Taggart D.P. Systematic review of therapies for stable coronary artery di­sease in diabetic patients. Ann. Thorac. Surg. 2015; 100 (6): 2383–2397. doi: 10.1016/j.athoracsur.2015.07.005.
  5. Flaherty J.D., Davidson C.J. Diabetes and coronary revascularization. JAMA. 2005; 293 (12): 1501–1508. doi: 10.1001/jama.293.12.1501.
  6. Kapur A., Hall R.J., Malik I.S. et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J. Am. Coll. Cardiol. 2010; 55 (5): ­432–440. doi: 10.1016/j.jacc.2009.10.014.
  7. Dauerman H.L. Percutaneous coronary intervention, diabetes mellitus, and death. J. Am. Coll. Cardiol. 2010; 55 (11): 1076–1079. doi: 10.1016/j.jacc.2009.09.056.
  8. Kassaian S.E., Goodarzynejad H., Boroumand M.A. et al. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc. Diabetol. 2012; (11): 82. doi: 10.1186/1475-2840-11-82.
  9. Byrne R.A., Joner M., Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur. Heart J. 2015; 36: 3320–3331. doi: 10.1093/eurheartj/ehv511.
  10. Koskinas K.C., Siontis G.C., Piccolo R. et al. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery di­sease complexity: Patient-level pooled analysis of 6081 patients. Circ. Cardiovasc. Interv. 2016; 9 (2): e003255. doi: 10.1161/CIRCINTERVENTIONS.115.003255.
  11. Sumin A.N., Bezdenezhnykh N.A., Bezdenezhnykh A.V. et al. Risk factors of major cardiovascular events in long-term period of coronary bypass in patients with ischemic heart disease and 2nd type diabetes mellitus. Rossiyskiy kardiologicheskiy zhurnal. 2015; (6): 30–37. (In Russ.)
  12. Bezdenezhnykh N.A., Sumin A.N., Barbarash O.L. Patient with diabetes and myocardial revascularization from evidence-based medicine positions: cardiologist’s ­opinion. Part 1. Rossiyskiy kardiologicheskiy zhurnal. 2017; (4): ­105–113. (In Russ.)
  13. Neumann F.-J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2018; 00: 1–96. doi: 10.1093/eurheartj/ehy658.
  14. Wang C.L., Hess C.N., Hiatt W.R. et al. Clinical update: Cardiovascular disease in diabetes mellitus: Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus — mechanisms, management, and cli­nical considerations. Circulation. 2016; 133: 2459–2502. doi: 10.1161/CIRCULATIONAHA.116.022194.
  15. Petursson P., Herlitz J., Lindqvist J. et al. Prevalence and severity of abnormal glucose regulation and its relation to long-term prognosis after coronary artery bypass grafting. Coron. Artery Dis. 2013; 24 (7): 577–582. doi: 10.1097/MCA.0b013e3283645c94.
  16. Subramaniam B., Lerner A., Novack V. et al. Increased glycemic variability in patients with elevated preoperative HbA1c predicts adverse outcomes following coro­nary artery bypass grafting surgery. Anesth. Analg. 2014; 118 (2): 277–287. doi: 10.1213/ANE.0000000000000100.
  17. Teplyakov A.T., Grakova E.V., Svarovskiy A.V. et al. Efficacy of endovascular coronary revascularization in patients with chd with reduced left ventricular. Kompleksnye problemy serdechno-sosudistykh zabolevaniy. 2017; 6 (1): ­79–91. (In Russ.)
  18. Lupanov V.P. Modern strategy, management and outcomes for stable ischemic heart disease patients. Kardiovaskulyarnaya terapiya i profilaktika. 2016; 15 (1): 77–83. (In Russ.)
  19. Michurova M.S., Kononenko I.V., Smirnova O.M., Kalashnikov V.Y. Effects of diabetes compensation by va­rious classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus. Sakharnyy diabet. 2014; 17 (1): 34–40. (In Russ.)
  20. Masoumi G., Frasatkhish R., Bigdelian H. et al. Insulin infusion on postoperative complications of coronary artery bypass graft in patients with diabetes mellitus. Res. Cardiovasc. Med. 2014; 3 (2): e17861. doi: 10.5812/cardiovascmed.17861.
  21. Umpierrez G., Cardona S., Pasquel F. et al. Rando­mized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG Trial. Diabetes Care. 2015; 38 (9): 1665–1672. doi: 10.2337/dc15-0303.
  22. Ujueta F., Weiss E.N., Sedlis S.P. et al. Glycemic control in coronary revascularization. Curr. Treat. Options. Cardiovasc. Med. 2016; 18 (2): 12. doi: 10.1007/s11936-015-0434-6.
  23. Standards of medical care in diabetes 2016: Summary of revisions. Diabetes сare. 2016; 39 (1): 4–5. doi: 10.2337/dc16-S003.

Views

Abstract - 44

PDF (Russian) - 48

PlumX


© 2019 Rustamova Y.K., Imanov G.G., Azizov V.A., Dzhakhangirov T.S., Maksimkin D.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Свидетельство о регистрации СМИ ЭЛ № ФС 77-75008 от 1 февраля 2019 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)